<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675881</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2013-1441</org_study_id>
    <nct_id>NCT02675881</nct_id>
  </id_info>
  <brief_title>Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®)</brief_title>
  <official_title>Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®) for Treatment of Focal Liver Malignancies: A Preliminary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing ablative zone is an essential part to improve technical success and long term&#xD;
      outcome in patient treated with radiofrequency ablation (RFA).&#xD;
&#xD;
      A combination of dual switching system and separable clustered electrode has been reported to&#xD;
      create large ablative zone in preclinical study.&#xD;
&#xD;
      Based on preclinical study, the investigators conducted a preliminary study in eligible 60&#xD;
      patients to measure whether this combination (dual switching system and separable clustered&#xD;
      electrode) improves technical success rate and local tumor progression rate over a year, in&#xD;
      comparison with historical control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing ablative zone is an essential part to improve technical success and long term&#xD;
      outcome in patient treated with radiofrequency ablation (RFA).&#xD;
&#xD;
      A combination of dual switching system and separable clustered electrode has been reported to&#xD;
      create large ablative zone in preclinical study.&#xD;
&#xD;
      Based on preclinical study, the investigators conducted a preliminary study in eligible 60&#xD;
      patients to measure whether this combination (dual switching system and separable clustered&#xD;
      electrode) improves technical success rate and local tumor progression rate over a year, in&#xD;
      comparison with historical control group using propensity score matching.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2013</start_date>
  <completion_date type="Actual">July 13, 2015</completion_date>
  <primary_completion_date type="Actual">April 8, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local tumor progression (LTP)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success on 1 months follow-up imaging after RFA (no residual/progressed tumor)</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of intrahepatic distant recurrence (IDR) after RFA</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of extrahepatic metastasis (EM) after RFA</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of complication of RFA</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of any possible complication related with RFA</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximal diameter of ablative zone</measure>
    <time_frame>7 day</time_frame>
    <description>Maximal diameter of ablative zone on post-RFA CT or MRI in a mm.</description>
  </other_outcome>
  <other_outcome>
    <measure>ablation time</measure>
    <time_frame>1 day</time_frame>
    <description>ablation time in a patient</description>
  </other_outcome>
  <other_outcome>
    <measure>Real time US fusion image feasibility</measure>
    <time_frame>1 day after RFA procedure</time_frame>
    <description>success or failure of accurate fusion between US and pre-RFA cross sectional images</description>
  </other_outcome>
  <other_outcome>
    <measure>Immediate evaluation of ablative zone via visual assess and pre-and post-RFA images registration.</measure>
    <time_frame>12 months</time_frame>
    <description>Prediction of LTP by classifying patients according to assessing ablative margin in each method on a four point scale (1: residual tumor, 4: ablative margin equal to or larger than 5mm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of ablative zone</measure>
    <time_frame>7 days</time_frame>
    <description>Volume of ablative zone on post-RFA CT or MRI in a mm3.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HCC</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>RFA DSM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients who undergo RFA using DSM and separable clustered electrodes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RFA SSM</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Historical control group consisted of patients underwent RFA in our institution with single switching mode (SSM) and single/ or multiple clustered electrodes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DSM</intervention_name>
    <description>Monopolar RFA using dual switching mode (DSM)</description>
    <arm_group_label>RFA DSM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>separable clustered electrode</intervention_name>
    <description>A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.</description>
    <arm_group_label>RFA DSM</arm_group_label>
    <other_name>Octopus(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatocellular carcinoma (according to AASLD guideline or LI-RADS)&#xD;
&#xD;
          -  histologically confirmed HCC&#xD;
&#xD;
          -  histologically confirmed or typical imaging feature of colorectal cancer liver&#xD;
             metastasis in patients with colorectal cancer AND&#xD;
&#xD;
          -  equal to or larger than 2cm, equal to or smaller than 5cm&#xD;
&#xD;
          -  available cross-sectional liver imaging within 30 days before RFA&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of local treatment on the index tumor&#xD;
&#xD;
          -  more than three tumors in a patient&#xD;
&#xD;
          -  tumors in central portion of portal vein or hepatic vein&#xD;
&#xD;
          -  Child-Pugh class C&#xD;
&#xD;
          -  vascular invasion by tumors&#xD;
&#xD;
          -  uncorrected coagulopathy&#xD;
&#xD;
          -  presence of multiple extrahepatic metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 31, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>RFA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

